Top Markets
Coin of the day
Clarity Pharmaceuticals Ltd Clarity Pharmaceuticals Ltd

Clarity Pharmaceuticals Ltd

CU6
Rang in aandelen #11775
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company,... Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
Aandeelprijs
$1.77
Laatst gesynchroniseerd: 2026-08-28
Marktkapitalisatie
$660.45M
Verandering (1 dag)
7.26%
Verandering (1 jaar)
-9.15%
Land
AU
Handel Clarity Pharmaceuticals Ltd (CU6)

Categorie

Dividendrendementgeschiedenis voor Clarity Pharmaceuticals Ltd (CU6)
Het dividendrendement (TTM) van Clarity Pharmaceuticals Ltd (aandelsymbool: CU6) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Clarity Pharmaceuticals Ltd (CU6) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten